Across all 6, the main weakness is the same: most cited evidence supports `pericyte dysfunction/loss ↔ BBB impairment`, not `pericyte senescence is the initiating lesion in human AD`. The strongest causal paper here is acute pericyte ablation, which is not equivalent to chronic senescence, and the human APOE4 paper is cross-sectional correlation rather than temporal causation. Sources: [PMID 25757756](https://pubmed.ncbi.nlm.nih.gov/25757756/), [21040844](https://pubmed.ncbi.nlm.nih.gov/21040844/), [36689812](https://pubmed.ncbi.nlm.nih.gov/36689812/), [26883501](https://pubmed.ncbi.nlm.nih.gov/26883501/), [31221773](https://pubmed.ncbi.nlm.nih.gov/31221773/), [36606305](https://pubmed.ncbi.nlm.nih.gov/36606305/), [31235908](https://pubmed.ncbi.nlm.nih.gov/31235908/), [32429102](https://pubmed.ncbi.nlm.nih.gov/32429102/).
1. `APOE4 -> primary pericyte senescence -> BBB leak before amyloid/tau`
- Weak evidence: [25757756](https://pubmed.ncbi.nlm.nih.gov/25757756/) shows more pericyte degeneration/BBB damage in AD APOE4 carriers, but within established AD tissue. It does not show senescence markers, temporal precedence, or exclude amyloid/CAA-driven vascular injury as the upstream event.
- Alternative mechanisms: APOE4 may impair endothelial BBB programs, astrocytic support, lipid transport, or Aβ clearance independently of pericyte senescence. Cerebral amyloid angiopathy is a major confound.
- Translational risk: iPSC BBB assembloids often under-model aging, immune tone, hemodynamic stress, and long-latency APOE4 effects. A positive in vitro result may overstate human druggability.
- Falsifying experiment: In APOE4 knock-in mice or human longitudinal biomarker cohorts, if amyloid/CAA or endothelial injury markers rise before pericyte senescence markers and BBB leak, this hypothesis is wrong.
2. `Pericyte senescence is sufficient to weaken BBB without proteinopathy`
- Weak evidence: [36689812](https://pubmed.ncbi.nlm.nih.gov/36689812/) and [26883501](https://pubmed.ncbi.nlm.nih.gov/26883501/) are mostly in vitro or accelerated-aging contexts. They support barrier impairment from senescent vascular cells, not specifically naturalistic pericyte-driven AD-like degeneration in vivo.
- Alternative mechanisms: Senescent endothelial cells may be the dominant lesion; pericyte senescence may be permissive rather than sufficient. Age-related basement membrane stiffening and inflammation could be the real drivers.
- Translational risk: Artificial `p16/p21` induction can create a nonphysiologic arrest state unlike endogenous senescence. Mouse BBB leak may not translate to human cognitive decline.
- Falsifying experiment: Pericyte-specific senescence induction in otherwise normal adult animals should produce durable BBB leak and downstream neural injury. If leak is mild/transient or requires concurrent endothelial/astrocyte aging, sufficiency fails.
3. `Aβ causes secondary pericyte senescence after contractile stress`
- Weak evidence: [31221773](https://pubmed.ncbi.nlm.nih.gov/31221773/) strongly supports Aβ-triggered pericyte-mediated constriction, but not senescence. [32429102](https://pubmed.ncbi.nlm.nih.gov/32429102/) is a review, not primary proof.
- Alternative mechanisms: Aβ may kill pericytes, dedifferentiate them, or impair metabolism without inducing a true senescence program. ROS/ET-1 may mainly reflect acute vasoactivity.
- Translational risk: Oligomer preparations vary; prolonged culture exposure can create artifact senescence. Contractile rescue in vitro may not rescue chronic in vivo degeneration.
- Falsifying experiment: In vivo, block `EDNRA` or ROS in an Aβ model and test whether senescence markers in lineage-traced pericytes still emerge. If senescence persists despite blocking contractile stress, the proposed sequence is wrong.
4. `BBB leak induces secondary pericyte senescence via TGFβ`
- Weak evidence: [36606305](https://pubmed.ncbi.nlm.nih.gov/36606305/) is about astrocytes, not pericytes. This is an extrapolation across cell types.
- Alternative mechanisms: Albumin/fibrinogen may act mainly on astrocytes, microglia, or endothelium, with pericyte changes secondary to inflammatory cross-talk rather than direct TGFβ stress.
- Translational risk: Microfluidic leak models can force nonphysiologic protein exposure and ignore pulsatility, immune cells, and clearance dynamics.
- Falsifying experiment: After isolated BBB opening in vivo, if pericyte senescence does not occur when astrocyte/microglial TGFβ signaling is blocked, then pericyte senescence is probably indirect, not a primary leak-driven response.
5. `Loss of pericyte-derived PTN is the key disease-modifying node`
- Weak evidence: [31235908](https://pubmed.ncbi.nlm.nih.gov/31235908/) uses acute pericyte ablation. That proves PTN matters after abrupt pericyte loss, not that senescent pericytes in AD mainly cause harm by suppressing `PTN`.
- Alternative mechanisms: The dominant pathology may still be hypoperfusion, BBB leak, impaired Aβ clearance, or inflammatory SASP. `PTN` loss could be one branch, not the node.
- Translational risk: PTN replacement could rescue neurons while leaving vasculopathy, edema risk, or maladaptive angiogenic signaling unresolved.
- Falsifying experiment: In a bona fide pericyte-senescence model, restore `PTN` selectively without removing senescent cells. If BBB leak, perfusion failure, and cognition remain poor, PTN is not the main disease-modifying mechanism.
6. `Pericyte senolysis will help only in an early biomarker-defined subgroup`
- Weak evidence: Mechanistically plausible, but mostly a therapeutic staging hypothesis built on indirect evidence from [25757756](https://pubmed.ncbi.nlm.nih.gov/25757756/) and [36689812](https://pubmed.ncbi.nlm.nih.gov/36689812/). Soluble `PDGFRβ` is not a clean readout of “senescent but still functional pericytes”; it may mark injury or loss.
- Alternative mechanisms: Benefit may depend more on amyloid burden, CAA, endothelial reserve, or immune state than on pericyte abundance alone.
- Translational risk: Senolytics are rarely cell-type specific. Killing residual mural cells in fragile capillaries could worsen leak and perfusion even in “early” patients.
- Falsifying experiment: Use lineage-traced, senescence-reporter pericyte models and compare senolysis versus senomorphic therapy across disease stages. If early senolysis does not outperform late treatment, or if benefit tracks amyloid/inflammation rather than pericyte state, the subgroup model fails.
Most important skeptical conclusion: the field has not yet separated `senescence`, `degeneration/loss`, `contractile dysfunction`, and `reactive stress state` in pericytes. A decisive study needs lineage-traced pericytes, true senescence reporters, timed perturbation, and temporal readouts of BBB leak, amyloid/CAA, tau, hypoperfusion, and neuronal injury in the same model.